Alnylam Receives New Issued U.S. Patent Broadly Covering Small Interfering RNAs and Strengthens Leadership in (Business Wire via Yahoo! Finance)

Alnylam Receives New Issued U.S. Patent Broadly Covering Small Interfering RNAs and Strengthens Leadership in (Business Wire via Yahoo! Finance)
CAMBRIDGE, Mass.—-July 18, 2006–Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that a new key fundamental patent from its exclusively held “Tuschl II” patent series was issued by the United States Patent and Trademark Office .